President Trump recently signed a wide-ranging executive order urging Congress to amend a crucial provision of a Biden-era law governing Medicare drug price negotiations, with the administration’s aim being to lower prices without kneecapping pharmaceutical industry investments in the research and development of innovative new drugs…
Read More
